CV Sciences (CVSI) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff pulls Wall Street to two-week lows as oil and yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- U.S. EV market shows signs of bottoming out: Bernstein
CV Sciences, Inc. Reports Second Quarter 2021 Financial Results
August 12, 2021 4:05 PM EDTSAN DIEGO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB: CVSI) (the Company, CV Sciences, our, us or we), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced its financial results for the quarter ended June 30, 2021.
Second Quarter 2021 and Recent Financial and Operating Highlights
Revenue of $5.1 million for second quarter of 2021, compared to $5.4 million for the second quarter of 2020;Gross margin of 44.7% for second quarter of 2021, improved from 43.0% for the second quarter of 2020;Total cash balance of $3.0 million at quarter end, compared to $4.5... More